ImmunityBio (IBRX) Non-Current Deferred Tax Liability (2015 - 2022)
ImmunityBio (IBRX) posted quarterly Non-Current Deferred Tax Liability of $162000.0 for Q2 2022, down 4.71% year-over-year from $170000.0 in Q2 2021, and little changed quarter-over-quarter from $162000.0 in Q1 2022.
ImmunityBio (IBRX) Non-Current Deferred Tax Liability (2015 - 2022) Analysis & Trends
ImmunityBio (IBRX) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $162000.0 the latest figure, recorded in Q2 2022.
- In Q2 2022, Non-Current Deferred Tax Liability fell 4.71% year-over-year to $162000.0; the TTM figure through Jun 2022 stood at $162000.0 (down 4.71% YoY), while the FY2021 annual figure was $162000.0, down 96.65% from the prior year.
- Non-Current Deferred Tax Liability steadied at $162000.0 in Q2 2022 per IBRX's latest filing, from $162000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $4.8 million in Q4 2020 and bottomed at $122000.0 in Q3 2018.
- Historically, Non-Current Deferred Tax Liability has averaged $658000.0 across 4 years, with a median of $170000.0 in 2021.
- Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability tumbled 96.65% — and 2022, when it retreated 4.71%.
- ImmunityBio's Non-Current Deferred Tax Liability stood at $122000.0 in 2018, then soared by 3865.57% to $4.8 million in 2020, then sank by 96.65% to $162000.0 in 2021, then changed by 0.0% to $162000.0 in 2022.
- Business Quant data shows IBRX's Non-Current Deferred Tax Liability at $162000.0 in Q2 2022, $162000.0 in Q1 2022, and $162000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 162,000.00 |
| Jun 30, 2022 | 162,000.00 |
| Mar 31, 2022 | 162,000.00 |
| Mar 31, 2022 | 162,000.00 |
| Dec 31, 2021 | 162,000.00 |
| Dec 31, 2021 | 162,000.00 |
| Sep 30, 2021 | 170,000.00 |
| Sep 30, 2021 | 170,000.00 |
| Jun 30, 2021 | 170,000.00 |
| Jun 30, 2021 | 170,000.00 |
| Mar 31, 2021 | 170,000.00 |
| Mar 31, 2021 | 170,000.00 |
| Dec 31, 2020 | 4.84 Mn |
| Dec 31, 2020 | 4.84 Mn |
| Sep 30, 2018 | 122,000.00 |
| Sep 30, 2018 | 122,000.00 |
| Jun 30, 2018 | 250,000.00 |
| Jun 30, 2018 | 250,000.00 |
| Mar 31, 2018 | 374,000.00 |
| Mar 31, 2018 | 374,000.00 |